Statin use before diabetes diagnosis and risk of microvascular disease: A nationwide nested matched study

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 11, 2014, Pages 894-900

  Nielsen, Sune F ^a   Nordestgaard, Børge G ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DENMARK; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; GANGRENE; GENERAL PRACTITIONER; HAZARD RATIO; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MIDDLE AGED; PROPENSITY SCORE; CASE CONTROL STUDY; CHEMICALLY INDUCED; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; FOOT; PATHOLOGY; RISK FACTOR;

AGED; CASE-CONTROL STUDIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; FEMALE; FOOT; GANGRENE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84916909531     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70173-1     Document Type: Article

References (23)

1. Sukhija R, Prayaga S, Marashdeh M, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009, 57:495-499.
2. Sasaki J, Iwashita M, Kono S Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006, 13:123-129.
3. Mehta JL Statins and altered glucose metabolism: a laboratory curiosity or a new disease?. J Am Coll Cardiol 2010, 56:680.
4. Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011, 305:2556-2564.
5. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:1924-1929.
6. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012, 380:565-571.
7. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
8. Belalcazar LM, Raghavan VA, Ballantyne CM Statin-induced diabetes: will it change clinical practice?. Diabetes Care 2009, 32:1941-1943.
9. Goldfine AB Statins: is it really time to reassess benefits and risks?. N Engl J Med 2012, 366:1752-1755.
10. Global guideline for type 2 diabetes 2005, Clinical Guidelines Task Force, International Diabetes Federation, Brussels.
11. Fine JP, Gray RJ A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
12. Donders ART, Heiden MGV, Stijnen T, Moyad MA A gentle introduction to imputation of missing values. J Clin Epidemiol 2006, 59:1087-1091.
13. Austin PC An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011, 46:399-424.
14. Knopp RH, Emden M, Smilde JG, Pocock SJ Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006, 29:1478-1485.
15. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016. Heart Protection Study Collaborative Group.
16. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
17. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010, 55:1209-1216.
18. Sabanayagam C, Liew G, Tai ES, et al. Relationship between glycated haemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes?. Diabetologia 2009, 52:1279-1289.
19. Gupta A, Gupta V, Thapar S, Bhansali A Lipid-lowering drug atorvastastin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004, 137:675-682.
20. Sen K, Misra A, Kumar A, Pandey RM Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002, 56:1-11.
21. Gordon B, Chang S, Kavanagh M, et al. The effects of lipid lowering on diabetic-retinopathy. Am J Ophthalmol 1991, 112:385-391.
22. Gaede P, Lund-Andersen H, Parving HH, Pedersen O Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
23. Fowler MJ Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008, 26:77-82.